Table 1.

Clinical characteristics of 22 patients with AITL

PatientSexAge, yPrior cancer history (treatment, dates)Date of AITL diagnosisTissue used for NGSBM bx dateIndication for BM bxMN diagnosed on BM bx (type)AITL-directed therapy prior to BM bxOutcomeOverall survival, mo*
1 M 61 None 11/12/15 LN 8/29/17 Worsening anemia, TCP on chemo that persisted 2 mo after completion No Chemo, ASCT, localized XRT DOD 22 
2† M 72 Prostate ca (XRT, 2015), smoldering MM (observation, 2016) 7/12/17 NA (NGS performed on FC sorted abnormal T cells from staging BM bx on 7/18/17) 8/28/19 New anemia, TCP 1.75 y after completion of chemo Yes (MDS-SLD) Chemo DOD; progressed to MDS-EB-2 28 
3 F 75 None 4/2/15 LN 1/14/16 Restaging at relapse No Chemo DOD 12 
4† M 67 None 5/4/11 LN 9/19/11 End of treatment bx No Chemo DOD 54 
5† F 68 Breast ca (chemo, XRT, hormonal therapy, 1997 and 2000) 12/23/15 Mesenteric mass 5/15/17 Evaluate disease status at relapse No Chemo DOD 46 
6† F 73 None 3/4/15 LN 3/20/15 Initial staging No None DOD 37 
7† M 44 None 8/9/17 Subcutaneous mass 9/15/17 Initial staging No None A w/o active D 27 
8† F 82 None 8/8/14 LN 12/18/15 Acutely worsening pancytopenia 12 mo after completion of chemo No Chemo AWD 63 
9† M 53 None 11/20/14 Skin 10/5/16 Persistent TCP 17 mo after completion of chemo No Chemo DOD 41 
10† F 63 None 4/20/16 LN 12/10/18 Persistent pancytopenia 6 mo after ASCT Yes (AML) Chemo, ASCT DOD 33 
11† M 71 None 3/23/15 LN 12/10/18 Worsening pancytopenia on clinical trial that persisted 1.75 mo after therapy cessation Yes (MDS-EB-1) Chemo A w/o D; progressed to AML 56 
12 M 69 None 8/7/18 LN 11/2/18 Repeat after possibility of MN raised on outside initial staging BM bx No Chemo A w/o active D 15 
13† M 74 None 7/16/19 LN 7/30/19 Initial staging No None AWD 4 
14 F 61 Classical Hodgkin lymphoma (chemo, XRT, 2007) 12/7/11 LN 1/5/18 Confirm relapse No Chemo, ASCT, TT A w/o D 95 
15† F 81 None 6/10/14 LN 6/13/14 Initial staging No None A w/o active D 65 
16 M 73 Prostate ca (active surveillance then resection in 2017) 2/19/15 LN 3/4/15 Initial staging No None A w/o D 57 
17† F 69 None 8/11/11 Skin 3/16/18 Persistent cytopenias 18 mo after relapse (on therapy) and assess disease status at first visit to our institution No Chemo, ASCT AWD 98 
18 M 71 Clear cell RCC (excision, 2004; recurrence/metastasis, observed since 2012) 3/5/15 LN 3/2/18 Staging of newly diagnosed laryngeal plasmacytoma No Chemo A w/o D 57 
19 M 67 None 7/12/17 LN 8/8/17 Initial staging No None DOD 7 
20† M 93 Melanoma (excision, 2016) 11/30/17 NA (NGS performed on FC sorted abnormal T-cells from staging BM bx on 12/22/17) 12/22/17 Initial staging No None AWD 19 
21† M 66 Bladder ca (excision, date unknown) 12/19/14 Spleen 1/8/18 Required for clinical trial enrollment at time of relapse No Chemo, TT AWD 59 
22† M 73 None 9/30/16 LN 7/11/19 Required for clinical trial enrollment at time of relapse Yes (CMML-0) Chemo, ASCT A w/o active D; persistent CMML 37 
PatientSexAge, yPrior cancer history (treatment, dates)Date of AITL diagnosisTissue used for NGSBM bx dateIndication for BM bxMN diagnosed on BM bx (type)AITL-directed therapy prior to BM bxOutcomeOverall survival, mo*
1 M 61 None 11/12/15 LN 8/29/17 Worsening anemia, TCP on chemo that persisted 2 mo after completion No Chemo, ASCT, localized XRT DOD 22 
2† M 72 Prostate ca (XRT, 2015), smoldering MM (observation, 2016) 7/12/17 NA (NGS performed on FC sorted abnormal T cells from staging BM bx on 7/18/17) 8/28/19 New anemia, TCP 1.75 y after completion of chemo Yes (MDS-SLD) Chemo DOD; progressed to MDS-EB-2 28 
3 F 75 None 4/2/15 LN 1/14/16 Restaging at relapse No Chemo DOD 12 
4† M 67 None 5/4/11 LN 9/19/11 End of treatment bx No Chemo DOD 54 
5† F 68 Breast ca (chemo, XRT, hormonal therapy, 1997 and 2000) 12/23/15 Mesenteric mass 5/15/17 Evaluate disease status at relapse No Chemo DOD 46 
6† F 73 None 3/4/15 LN 3/20/15 Initial staging No None DOD 37 
7† M 44 None 8/9/17 Subcutaneous mass 9/15/17 Initial staging No None A w/o active D 27 
8† F 82 None 8/8/14 LN 12/18/15 Acutely worsening pancytopenia 12 mo after completion of chemo No Chemo AWD 63 
9† M 53 None 11/20/14 Skin 10/5/16 Persistent TCP 17 mo after completion of chemo No Chemo DOD 41 
10† F 63 None 4/20/16 LN 12/10/18 Persistent pancytopenia 6 mo after ASCT Yes (AML) Chemo, ASCT DOD 33 
11† M 71 None 3/23/15 LN 12/10/18 Worsening pancytopenia on clinical trial that persisted 1.75 mo after therapy cessation Yes (MDS-EB-1) Chemo A w/o D; progressed to AML 56 
12 M 69 None 8/7/18 LN 11/2/18 Repeat after possibility of MN raised on outside initial staging BM bx No Chemo A w/o active D 15 
13† M 74 None 7/16/19 LN 7/30/19 Initial staging No None AWD 4 
14 F 61 Classical Hodgkin lymphoma (chemo, XRT, 2007) 12/7/11 LN 1/5/18 Confirm relapse No Chemo, ASCT, TT A w/o D 95 
15† F 81 None 6/10/14 LN 6/13/14 Initial staging No None A w/o active D 65 
16 M 73 Prostate ca (active surveillance then resection in 2017) 2/19/15 LN 3/4/15 Initial staging No None A w/o D 57 
17† F 69 None 8/11/11 Skin 3/16/18 Persistent cytopenias 18 mo after relapse (on therapy) and assess disease status at first visit to our institution No Chemo, ASCT AWD 98 
18 M 71 Clear cell RCC (excision, 2004; recurrence/metastasis, observed since 2012) 3/5/15 LN 3/2/18 Staging of newly diagnosed laryngeal plasmacytoma No Chemo A w/o D 57 
19 M 67 None 7/12/17 LN 8/8/17 Initial staging No None DOD 7 
20† M 93 Melanoma (excision, 2016) 11/30/17 NA (NGS performed on FC sorted abnormal T-cells from staging BM bx on 12/22/17) 12/22/17 Initial staging No None AWD 19 
21† M 66 Bladder ca (excision, date unknown) 12/19/14 Spleen 1/8/18 Required for clinical trial enrollment at time of relapse No Chemo, TT AWD 59 
22† M 73 None 9/30/16 LN 7/11/19 Required for clinical trial enrollment at time of relapse Yes (CMML-0) Chemo, ASCT A w/o active D; persistent CMML 37 

A w/o D, alive without evidence of disease (AITL); AML, acute myeloid leukemia; ASCT, autologous stem cell transplant; AWD, alive with disease (AITL); bx, biopsy; ca, cancer; chemo, chemotherapy; CMML-0, chronic myelomonocytic leukemia 0; DLBCL, diffuse large B-cell lymphoma; DOD, dead of disease; F, female; LAD, lymphadenopathy; LN, lymph node; M, male; MDS-EB-1, myelodysplastic syndrome with excess blasts 1; MDS-EB-2, myelodysplastic syndrome with excess blasts 2; MDS-SLD, myelodysplastic syndrome with single lineage dysplasia; MM, multiple myeloma; NA, not applicable; RCC, renal cell carcinoma; TCP, thrombocytopenia; TT, targeted therapy; XRT, radiation.

*

Overall survival indicates the time from AITL diagnosis to date of death or last follow-up.

†

Patients with evidence of shared mutations in their AITL and non-AITL BM compartment.

View Large
This Feature Is Available To Subscribers Only

or Create an Account

Close Modal
Close Modal